New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2012
16:19 EDTHPQ, ILMN, AVID, CSCO, FIO, MIPS, MRC, FET, OAK, RHHBYOn The Fly: Closing Wrap
Stocks on Wall Street rose significantly on indications from the New York Fed that interest rates will likely remain low. Stock futures were slightly above fair value in early trading but weakened following the slightly disappointing jobless claims data. The futures action led to a relatively quiet open for the market but it soon picked up momentum to the upside. The market moved up roughly 0.5% in early trading, then spurted higher before noon. Investors rallied the market after last night’s comments from Fed president Janet Yellen, who said the Fed should be ready to ease its fiscal stance if the economy weakened while also being willing to raise rates if the economy warranted. Investors grabbed onto the dovish comments and lifted the market for the second day in a row… ECONOMIC EVENTS: In the U.S., 380K initial jobless claims were filed last week, versus the expected 355K. 3.25M continuing claims were reported, versus the expected 3.33M. Producer prices for the month of March were flat, versus the expected increase of 0.3%. The core PPI reading, however, rose 0.3%, versus the expected increase of 0.2%. The trade balance report showed a deficit of $46.0B, versus expectations for a deficit of $51B. In Europe, Italy's short-term borrowing costs rose at auction... COMPANY NEWS: Hewlett-Packard (HPQ) was a beneficiary of two reports from Gartner and IDC, each of which showed that global shipments of personal computers rose in Q1, with HP remaining the top PC maker by volume. On the day, Hewlett-Packard stock was up 7.18% to $25.09… Oaktree Capital (OAK), Forum Energy Technologies (FET) and MRC Global (MRC) all traded for the first time today, though none of the companies' stocks moved much compared to their IPO prices... MAJOR MOVERS: Among the notable gainers were MIPS Technologies (MIPS), which jumped 26.30%, to $6.58, after Bloomberg reported that Goldman Sachs (GS) had been hired to advise it on a possible sale of the company, and Fusion-io (FIO), which rose 14.80%, to $28.31, following a note to investors from Piper Jaffray saying it believes the company is working on a new original equipment manufacturer deal with Cisco (CSCO)… Noteworthy losers included Avid Technology (AVID), which lost 17.32%, to $8.50, after the company announced it expects to post Q1 revenues lower than last year, and Illumina (ILMN), which dropped 5.82%, to $49.51, after Roche Holding’s (RHHBY) CEO said he doesn’t see any reason to raise the current offer for the company… INDICES: The Dow gained 181.19 points, or 1.41%, to 12,986.58; the Nasdaq rose 39.09 points, or 1.30%, to 3,055.55; and the S&P 500 added 18.86 points, or 1.38%, to 1,387.57.
News For HPQ;OAK;FET;MRC;MIPS;FIO;CSCO;AVID;ILMN;RHHBY From The Last 14 Days
Check below for free stories on HPQ;OAK;FET;MRC;MIPS;FIO;CSCO;AVID;ILMN;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 13, 2014
13:13 EDTRHHBYInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
13:00 EDTRHHBYInterMune received takeover bids from Sanofi, Roche, Bloomberg says
10:43 EDTCSCOOptions with increasing implied volatility
Options with increasing implied volatility: PSEC CSCO XONE NDLS
07:55 EDTHPQHP free cash flow upside thesis intact, says Brean Capital
Subscribe for More Information
07:22 EDTCSCOGoldman pushes Cisco head to step-up software, Bloomberg says
Subscribe for More Information
August 12, 2014
15:03 EDTCSCOArista Networks faces rougher road ahead, WSJ says
Arista Networks (ANET) shares have been strong since the company's IPO and its growth prospects make a "good case for a decent premium," but the current valuation gap compared to its peers "seems wide", according to The Wall Street Journal's "Heard on the Street" column, which noted that Cisco (CSCO) has the resources and incentive to push back against Arista's attempts to take share in network switches. Reference Link
13:47 EDTOAKOaktree Capital upgraded to Buy from Neutral at BofA/Merrill (pre-open)
Subscribe for More Information
13:04 EDTCSCOCisco technical comments before earnings
In the last three months the stock has outperformed the broader averages, rising by nearly 9%. The trend in that time has been up, but with the bulk of gains having been realized near the start of the period. There was one larger bump up in price that was corrected, but that high at $26.08 now becomes an objective for bulls to take out on the upside on good news. The reason for this is that the $26 to $26.50 area forms a big double top when viewed on a 2-year daily chart. The bulls need to break this area of resistance for the stock to become long-term bullish. If they can manage that, next resistance above $26.50 would be at $27.74. If the news disappoints, that potentially bearish double top pattern could asset itself. The $23.50 area on a break lower would be the first test. The middle of the "M" pattern would be at $21.27.
12:49 EDTCSCOCisco August 25 straddle priced for 4.7% move into Q4
Subscribe for More Information
10:31 EDTHPQEx-Autonomy CFO accuses HP of agreement cover-up, Re/code says
Subscribe for More Information
10:00 EDTILMNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:42 EDTCSCOCisco August volatility increases into Q4 and outlook
Subscribe for More Information
06:06 EDTCSCOCisco planning to fire 300 employees in Israel, Globes reports
As part of a worldwide streamlining effort, Cisco is planning to fire 300 employees in Israel, Globes reports. Reference Link
August 11, 2014
18:07 EDTILMNIllumina initiated with a Buy at Stifel
Target $200.
15:24 EDTHPQBloomberg to hold a summit
Silicon Valley 2014 Cybersecurity Summit to be held in Palo Alto, California on August 12.
05:55 EDTCSCOCisco expected to report solid Q4 results at Wells Fargo
Subscribe for More Information
05:53 EDTRHHBYCuris shares look attractive, says Piper Jaffray
Subscribe for More Information
August 8, 2014
11:33 EDTRHHBYRoche submits supplemental Biologics License application to FDA for Lucentis
Subscribe for More Information
08:31 EDTCSCOMorgan Stanley expects Cisco to report good results, conservative outlook
Morgan Stanley expects Cisco to report results of 54c/$12.26B vs. consensus of 53c/$12.14B and said checks indicate the enterprise market is improving. The firm expects Cisco's outlook to be conservative and said concerns over rapid software-defined networking adoption and margin impact are overblown. Shares are Overweight rated with a $30 price target.
August 7, 2014
14:05 EDTRHHBYPTC Therapeutics reports publication of preclinical study results in SMA models
PTC Therapeutics (PTCT) announced that he journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy or SMA. Stuart Peltz, CEO of PTC Therapeutics, said, "Using the experience and expertise in RNA biology we have gained at PTC over the last 16 years, we used our alternative splicing technology to identify and subsequently optimize investigational compounds that target the SMN2 splicing to produce the SMN protein. Our unique partnership with Roche and the SMA Foundation has allowed this project to rapidly move into clinical development." Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche (RHHBY), said, "Although still preclinical, these results demonstrate how SMN2 splicing modifiers could correct the molecular deficit that causes SMA. This study represents an important step towards developing a potential therapeutic option for this devastating and currently untreatable condition. Early clinical trials are currently underway to determine the safety and tolerability of this approach."
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use